ScholarDeck

AI / informaticsJournal of clinical medicine · 2026

Functional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathy.

Giulia Gregori, Chiara Centini, Lorenzo Mangoni … Marco Lupidi

OphthalmologyAI / informatics

Adding eplerenone to photodynamic therapy was linked to more complete subretinal fluid resolution

Functional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathy.

Giulia Gregori … Marco Lupidi

Journal of clinical medicine · 2026

Background

To evaluate whether the combination of oral eplerenone and half-dose full-fluence photodynamic therapy (HD-FF PDT) provides greater efficacy than HD-FF PDT alone in persistent central serous chorioretinopathy (central serous chorioretinopathy).

Methods

Functional and morphological data collected at baseline and at 1, 3, and 6 months after treatment were retrospectively reviewed.

n = 53 eyes

Results

in Group B, subretinal fluid fully cleared far more often than in Group A

Group B

77%

Group A

22%

More results

Best-corrected visual acuity improved more significantly in Group B at 1 and 6 months ( p = 0.032 and p = 0.009, respectively).

At 6 months, subretinal fluid volume (subretinal fluid volume), quantified by AI-based OCT analysis, was significantly lower in the combined therapy group ( p = 0.014).

“

Conclusion

Although HD-FF PDT remains the standard treatment for persistent central serous chorioretinopathy, adjunctive therapy with the mineralocorticoid receptor antagonist eplerenone may enhance subretinal fluid reabsorption and improve mid-term anatomical and functional outcomes.

Post

Functional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathy.

Adding eplerenone to photodynamic therapy was linked to more complete subretinal fluid resolution

Related papers